Immune reconstitution and strategies for rebuilding the immune system after haploidentical stem cell transplantation

Annals of the New York Academy of Sciences

Volumn 1266, Issue 1, 2012, Pages 161-170

  Oevermann, Lena ^a   Lang, Peter ^a   Feuchtinger, Tobias ^a   Schumm, Michael ^a   Teltschik, Heiko Manuel ^a   Schlegel, Patrick ^a   Handgretinger, Rupert ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Adoptive transfer; Haploidentical transplantation; Immune reconstitution; T cell recovery

Indexed keywords

CYCLOPHOSPHAMIDE; GROWTH HORMONE; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2; KERATINOCYTE GROWTH FACTOR;

ADAPTIVE IMMUNITY; ARTICLE; CAUSE OF DEATH; CD4+ CD25+ T LYMPHOCYTE; DONOR; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; NATURAL KILLER CELL; NONHUMAN; STEM CELL TRANSPLANTATION; T CELL DEPLETION; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 84865365080     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06606.x     Document Type: Article

References (63)

1. Thomas, E.D., C.D. Buckner, M. Banaji, et al 1977. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 49: 511-533.
2. Gyurkocza, B., A. Rezvani & R.F. Storb 2010. Allogeneic hematopoietic cell transplantation: the state of the art. Expert Rev. Hematol. 3: 285-299.
3. Wagner, J.E. & E. Gluckman 2010. Umbilical cord blood transplantation: the first 20 years. Semin. Hematol. 47: 3-12.
4. Seggewiss, R. & H. Einsele 2010. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood 115: 3861-3868.
5. Powles, R.L., G.R. Morgenstern, H.E. Kay, et al 1983. Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. Lancet 1: 612-615.
6. Mehta, J., S. Singhal, A.P. Gee, et al 2004. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients. Bone Marrow Transplant. 33: 389-396.
7. Schumm, M., P. Lang, G. Taylor, et al 1999. Isolation of highly purified autologous and allogeneic peripheral CD34+ cells using the CliniMACS device. J. Hematother. 8: 209-218.
8. Handgretinger, R., T. Klingebiel, P. Lang, et al 2001. Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant. 27: 777-783.
9. Aversa, F., A. Tabilio, A. Velardi, et al 1998. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N. Engl. J. Med. 339: 1186-1193.
10. Aversa, F., A. Terenzi, A. Tabilio, et al 2005. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J. Clin. Oncol. 23: 3447-3454.
11. Gordon, P.R., T. Leimig, I. Mueller, et al 2002. A large-scale method for T cell depletion: towards graft engineering of mobilized peripheral blood stem cells. Bone Marrow Transplant. 30: 69-74.
12. Barfield, R.C., M. Otto, J. Houston, et al 2004. A one-step large-scale method for T- and B-cell depletion of mobilized PBSC for allogeneic transplantation. Cytotherapy 6: 1-6.
13. Chaleff, S., M. Otto, R.C. Barfield, et al 2007. A large-scale method for the selective depletion of alphabeta T lymphocytes from PBSC for allogeneic transplantation. Cytotherapy 9: 746-754.
14. Huang, X.J., D.H. Liu, K.Y. Liu, et al 2006. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant. 38: 291-297.
15. Huang, X.J. & Y.J. Chang 2011. Unmanipulated HLA-mismatched/haploidentical blood and marrow hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant 17: 197-204.
16. Lu, D.P., L. Dong, T. Wu, et al 2006. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 107: 3065-3073.
17. Luznik, L., P.V. O'Donnell, H.J. Symons, et al 2008. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol. Blood Marrow Transplant. 14: 641-650.
18. Luznik, L., J. Bolanos-Meade, M. Zahurak, et al 2010. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 115: 3224-3230.
19. Klingebiel, T., J. Cornish, M. Labopin, et al 2010. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood 115: 3437-3446.
20. Ciceri, F., M. Labopin, F. Aversa, et al 2008. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 112: 3574-3581.
21. Walker, I., N. Shehata, G. Cantin, et al 2004. Canadian multicenter pilot trial of haploidentical donor transplantation. Blood Cells Mol. Dis. 33: 222-226.
22. Hale, G.A., K.A. Kasow, K. Gan, et al 2005. Haploidentical stem cell transplantation with CD3 depleted mobilized peripheral blood stem cell grafts for children with hematologic malignancies. ASH Annual Meeting Abstracts. 106: 2910.
23. Hale, G.A., K.A. Kasow, R. Madden, et al 2006. Mismatched family member donor transplantation for patients with refractory hematologic malignancies: long-term followup of a prospective clinical trial. ASH Annual Meeting Abstracts. 108: 3137.
24. Chen, X., G.A. Hale, R. Barfield, et al 2006. Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies. Br. J. Haematol. 135: 524-532.
25. Federmann, B., M. Hagele, M. Pfeiffer, et al 2011. Immune reconstitution after haploidentical hematopoietic cell transplantation: impact of reduced intensity conditioning and CD3/CD19 depleted grafts. Leukemia 25: 121-129.
26. Handgretinger, R., X. Chen, M. Pfeiffer, et al 2007. Feasibility and outcome of reduced-intensity conditioning in haploidentical transplantation. Ann. N.Y. Acad. Sci. 1106: 279-289.
27. Dufort, G., S. Pisano, A. Incoronato, et al 2012. Feasibility and outcome of haploidentical SCT in pediatric high-risk hematologic malignancies and Fanconi anemia in Uruguay. Bone Marrow Transplant 47: 663-668.
28. Palma, J., L. Salas, F. Carrion, et al 2012. Haploidentical stem cell transplantation for children with high-risk leukemia. Pediatr. Blood Cancer [Epub ahead of print].
29. Leung, W., D. Campana, J. Yang, et al 2011. High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood 118: 223-230.
30. Godder, K.T., P.J. Henslee-Downey, J. Mehta, et al 2007. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant. 39: 751-757.
31. Handgretinger, R., P. Lang, T.F. Feuchtinger, et al 2011. Transplantation of TcR{alpha}{beta}/CD19 depleted stem cells from haploidentical donors: robust engraftment and rapid immune reconstitution in children with high risk leukemia. ASH Annual Meeting Abstracts. 118: 1005.
32. Rizzieri, D.A., L.P. Koh, G.D. Long, et al 2007. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J. Clin. Oncol. 25: 690-697.
33. Luznik, L., L.W. Engstrom, R. Iannone & E.J. Fuchs 2002. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol. Blood Marrow Transplant. 8: 131-138.
34. Munchel, A., C. Kesserwan, H.J. Symons, et al 2011. Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide. Pediatr. Rep. 3(Suppl 2):e15.
35. Tuve, S., J. Gayoso, C. Scheid, et al 2011. Haploidentical bone marrow transplantation with post-grafting cyclophosphamide: multicenter experience with an alternative salvage strategy. Leukemia 25: 880-883.
36. Fuji, S., M. Kapp & H. Einsele 2012. Challenges to preventing infectious complications, decreasing re-hospitalizations, and reducing cost burden in long-term survivors after allogeneic hematopoietic stem cell transplantation. Semin. Hematol. 49: 10-14.
37. Min, D., P.A. Taylor, A. Panoskaltsis-Mortari, et al 2002. Protection from thymic epithelial cell injury by keratinocyte growth factor: a new approach to improve thymic and peripheral T-cell reconstitution after bone marrow transplantation. Blood 99: 4592-4600.
38. Levine, J.E., B.R. Blazar, T. Defor, J.L. Ferrara & D.J. Weisdorf 2008. Long-term follow-up of a phase I/II randomized, placebo-controlled trial of palifermin to prevent graft-versus-host disease (GVHD) after related donor allogeneic hematopoietic cell transplantation (HCT). Biol. Blood Marrow Transplant. 14: 1017-1021.
39. Murphy, W.J., S.K. Durum, M.R. Anver & D.L. Longo 1992. Immunologic and hematologic effects of neuroendocrine hormones. Studies on DW/J dwarf mice. J. Immunol. 148: 3799-3805.
40. Knyszynski, A., S. Dler-Kunin & A. Globerson 1992. Effects of growth hormone on thymocyte development from progenitor cells in the bone marrow. Brain Behav. Immun. 6: 327-340.
41. Soiffer, R.J., C. Murray, K. Cochran, et al 1992. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood 79: 517-526.
42. Perillo, A., L. Pierelli, A. Battaglia, et al 2002. Administration of low-dose interleukin-2 plus G-CSF/EPO early after autologous PBSC transplantation: effects on immune recovery and NK activity in a prospective study in women with breast and ovarian cancer. Bone Marrow Transplant. 30: 571-578.
43. Nadal, E., A. Fowler, E. Kanfer, et al 2004. Adjuvant interleukin-2 therapy for patients refractory to donor lymphocyte infusions. Exp. Hematol. 32: 218-223.
44. Fry, T.J., E. Connick, J. Falloon, et al 2001. A potential role for interleukin-7 in T-cell homeostasis. Blood 97: 2983-2990.
45. Sportes, C., F.T. Hakim, S.A. Memon, et al 2008. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J. Exp. Med. 205: 1701-1714.
46. Alpdogan, O., S.J. Muriglan, J.M. Eng, et al 2003. IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation. J. Clin. Invest. 112: 1095-1107.
47. Storek, J., T. Gillespy, III, H. Lu, et al 2003. Interleukin-7 improves CD4 T-cell reconstitution after autologous CD34 cell transplantation in monkeys. Blood 101: 4209-4218.
48. Rubinstein, M.P., A.N. Kadima, M.L. Salem, et al 2002. Systemic administration of IL-15 augments the antigen-specific primary CD8+ T cell response following vaccination with peptide-pulsed dendritic cells. J. Immunol. 169: 4928-4935.
49. Lin, S.J., P.J. Cheng, D.C. Yan, P.T. Lee & H.S. Hsaio 2006. Effect of interleukin-15 on alloreactivity in umbilical cord blood. Transpl. Immunol. 16: 112-116.
50. Leung, W. 2011. Use of NK cell activity in cure by transplant. Br. J. Haematol. 155: 14-29.
51. Brehm, C., S. Huenecke, A. Quaiser, et al 2011. IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study. PLoS. One 6: e27351.
52. Rizzieri, D.A., R. Storms, D.F. Chen, et al 2010. Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 16: 1107-1114.
53. Passweg, J.R., A. Tichelli, S. Meyer-Monard, et al 2004. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 18: 1835-1838.
54. Rubnitz, J.E., H. Inaba, R.C. Ribeiro, et al 2010. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J. Clin. Oncol. 28: 955-959.
55. Amrolia, P.J., G. Muccioli-Casadei, H. Huls, et al 2006. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 108: 1797-1808.
56. Dodero, A., C. Carniti, A. Raganato, et al 2009. Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood 113: 4771-4779.
57. Feuchtinger, T., K. Opherk, W.A. Bethge, et al 2010. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 116: 4360-4367.
58. Feuchtinger, T., S. Matthes-Martin, C. Richard, et al 2006. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br. J. Haematol. 134: 64-76.
59. Lugthart, G., S.J. Albon, I. Ricciardelli, et al 2012. Simultaneous generation of multivirus-specific and regulatory T cells for adoptive immunotherapy. J. Immunother. 35: 42-53.
60. Perruccio, K., F. Topini, A. Tosti, et al 2008. Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation. Blood Cells Mol. Dis. 40: 76-83.
61. Mielke, S., R. Nunes, K. Rezvani, et al 2008. A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. Blood 111: 4392-4402.
62. Edinger, M., P. Hoffmann, J. Ermann, et al 2003. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med. 9: 1144-1150.
63. Di, I.M., F. Falzetti, A. Carotti, et al 2011. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 117: 3921-3928.